Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 87% ± 11% | |
lung | 20 studies | 55% ± 19% | |
intestine | 14 studies | 41% ± 21% | |
kidney | 9 studies | 49% ± 27% | |
liver | 7 studies | 45% ± 26% | |
bone marrow | 6 studies | 49% ± 31% | |
lymph node | 6 studies | 69% ± 23% | |
pancreas | 5 studies | 45% ± 18% | |
brain | 5 studies | 43% ± 23% | |
placenta | 5 studies | 42% ± 15% | |
heart | 5 studies | 22% ± 4% | |
uterus | 5 studies | 63% ± 16% | |
prostate | 5 studies | 51% ± 15% | |
esophagus | 4 studies | 40% ± 14% | |
breast | 4 studies | 69% ± 3% | |
eye | 3 studies | 34% ± 26% | |
adipose | 3 studies | 52% ± 24% | |
adrenal gland | 3 studies | 54% ± 26% | |
thymus | 3 studies | 42% ± 18% | |
skin | 3 studies | 49% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 34317.66 | 1444 / 1445 | 100% | 719.93 | 183 / 183 |
lung | 100% | 140449.60 | 578 / 578 | 100% | 873.95 | 1153 / 1155 |
thymus | 100% | 51135.73 | 651 / 653 | 100% | 901.83 | 605 / 605 |
intestine | 100% | 40598.28 | 966 / 966 | 100% | 830.71 | 525 / 527 |
kidney | 100% | 41183.64 | 89 / 89 | 100% | 1234.91 | 897 / 901 |
bladder | 100% | 36297.24 | 21 / 21 | 99% | 814.06 | 498 / 504 |
uterus | 100% | 46863.61 | 170 / 170 | 99% | 889.98 | 453 / 459 |
skin | 99% | 47082.19 | 1789 / 1809 | 99% | 1311.15 | 469 / 472 |
breast | 100% | 73413.86 | 459 / 459 | 98% | 682.81 | 1094 / 1118 |
prostate | 99% | 32324.82 | 243 / 245 | 96% | 524.00 | 484 / 502 |
stomach | 94% | 25317.99 | 337 / 359 | 99% | 732.59 | 284 / 286 |
ovary | 98% | 25178.13 | 177 / 180 | 95% | 468.42 | 407 / 430 |
adrenal gland | 98% | 25539.37 | 252 / 258 | 90% | 422.36 | 208 / 230 |
liver | 81% | 20312.68 | 184 / 226 | 99% | 622.91 | 401 / 406 |
brain | 54% | 10027.28 | 1415 / 2642 | 99% | 599.99 | 698 / 705 |
pancreas | 44% | 7319.76 | 145 / 328 | 99% | 921.40 | 177 / 178 |
adipose | 100% | 82903.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 1112.57 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 1870.05 | 29 / 29 |
peripheral blood | 100% | 188792.40 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 123505.20 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 395.21 | 1 / 1 |
blood vessel | 99% | 37224.87 | 1327 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 1169.29 | 44 / 45 |
heart | 96% | 23554.46 | 824 / 861 | 0% | 0 | 0 / 0 |
muscle | 60% | 9625.70 | 479 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002717 | Biological process | positive regulation of natural killer cell mediated immunity |
GO_0002639 | Biological process | positive regulation of immunoglobulin production |
GO_0032753 | Biological process | positive regulation of interleukin-4 production |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0002476 | Biological process | antigen processing and presentation of endogenous peptide antigen via MHC class Ib |
GO_0002715 | Biological process | regulation of natural killer cell mediated immunity |
GO_0002486 | Biological process | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent |
GO_0045087 | Biological process | innate immune response |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0032819 | Biological process | positive regulation of natural killer cell proliferation |
GO_0032736 | Biological process | positive regulation of interleukin-13 production |
GO_0002519 | Biological process | natural killer cell tolerance induction |
GO_0002729 | Biological process | positive regulation of natural killer cell cytokine production |
GO_0001815 | Biological process | positive regulation of antibody-dependent cellular cytotoxicity |
GO_0001916 | Biological process | positive regulation of T cell mediated cytotoxicity |
GO_0032759 | Biological process | positive regulation of TRAIL production |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0045953 | Biological process | negative regulation of natural killer cell mediated cytotoxicity |
GO_0042270 | Biological process | protection from natural killer cell mediated cytotoxicity |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0032815 | Biological process | negative regulation of natural killer cell activation |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0032816 | Biological process | positive regulation of natural killer cell activation |
GO_2001187 | Biological process | positive regulation of CD8-positive, alpha-beta T cell activation |
GO_0036037 | Biological process | CD8-positive, alpha-beta T cell activation |
GO_2000566 | Biological process | positive regulation of CD8-positive, alpha-beta T cell proliferation |
GO_0002477 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class Ib |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0055038 | Cellular component | recycling endosome membrane |
GO_0009986 | Cellular component | cell surface |
GO_0000139 | Cellular component | Golgi membrane |
GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
GO_0030670 | Cellular component | phagocytic vesicle membrane |
GO_0042612 | Cellular component | MHC class I protein complex |
GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
GO_0032398 | Cellular component | MHC class Ib protein complex |
GO_0042608 | Molecular function | T cell receptor binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0042288 | Molecular function | MHC class I protein binding |
GO_0046703 | Molecular function | natural killer cell lectin-like receptor binding |
GO_0030881 | Molecular function | beta-2-microglobulin binding |
GO_0005515 | Molecular function | protein binding |
GO_0042605 | Molecular function | peptide antigen binding |
Gene name | HLA-E |
Protein name | HLA-E protein HLA-E MHC class I antigen HLA-E (Leucocyte Antigen) (MHC class I antigen) (MHC class Ib antigen) (Major histocompatibility complex, class I, E) MHC class Ib antigen MHC antigen Leucocyte Antigen HLA class I histocompatibility antigen, alpha chain E (MHC class I antigen E) [Cleaved into: Soluble HLA class I histocompatibility antigen, alpha chain E (sHLA-E)] Major histocompatibility complex, class I, E |
Synonyms | hCG_26010 HLA-6.2 HLAE |
Description | FUNCTION: Non-classical major histocompatibility class Ib molecule involved in immune self-nonself discrimination. In complex with B2M/beta-2-microglobulin binds nonamer self-peptides derived from the signal sequence of classical MHC class Ia molecules (VL9 peptides - VMAPRT[V/L][L/V/I/F]L) . Peptide-bound HLA-E-B2M heterotrimeric complex primarily functions as a ligand for natural killer (NK) cell inhibitory receptor KLRD1-KLRC1, enabling NK cells to monitor the expression of other MHC class I molecules in healthy cells and to tolerate self . Upon cellular stress, preferentially binds signal sequence-derived peptides from stress-induced chaperones and is no longer recognized by NK cell inhibitory receptor KLRD1-KLRC1, resulting in impaired protection from NK cells . Binds signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules and acts as a ligand for NK cell activating receptor KLRD1-KLRC2, likely playing a role in the generation and effector functions of adaptive NK cells and in maternal-fetal tolerance during pregnancy . Besides self-peptides, can also bind and present pathogen-derived peptides conformationally similar to VL9 peptides to alpha-beta T cell receptor (TCR) on unconventional CD8-positive cytotoxic T cells, ultimately triggering antimicrobial immune response . Presents HIV gag peptides (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) predominantly to CD8-positive T cell clones expressing a TRAV17-containing TCR, triggering HLA-E-restricted T cell responses . Presents mycobacterial peptides to HLA-E-restricted CD8-positive T cells eliciting both cytotoxic and immunoregulatory functions . .; FUNCTION: (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. .; FUNCTION: (Microbial infection) May bind HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition. .; FUNCTION: (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells . Binds SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening of antiviral immune surveillance . . |
Accessions | ENST00000383597.6 S4W2A6 ENST00000415649.4 ENST00000415289.4 A0A0F7W1Q1 A0A5C0C6I5 W0NXW9 Q2L6I5 Q6KBZ5 ENST00000425603.4 A0A4E9D3W4 A0A7L7TM74 Q9TNU7 A0A4E9DQ67 ENST00000444683.4 Q6DU50 ENST00000376630.5 Q9MW44 A0A4E9E4P1 A0A0A8LFF7 A0A0F7WBW2 P13747 ENST00000427936.4 O19682 I3RW89 S5RFZ0 A0A4E9E9K8 W0NTJ0 |